Scenarios of future cancer incidence were developed and analysed using the PREVENT software in order to estimate the future burden in case of maximal implementation of effective interventions. In order to do this, existing software (PREVENT, developed 20 years ago ) was adapted to the needs and wishes of EUROCADET. In summary, PREVENT underwent the following modifications:
- A dimension to account for changes in disease occurrence was added (previously not existing)
- The lag time between exposure and changes in disease risk can now be modelled into different shapes (previously only linear).
- Risk factors with a continuous distribution can now be modelled. (Previously only categorical)
- A cohort dimension was added to allow assessment of the impact of future prevalence of smoking on smoking-related cancers (previously not existing).
- The possibility to model quit and initiation rates of smoking was added
- Bugs in the software have been fixed.
- A user-manual has been developed
- 2-day courses for the use of the Prevent-Eurocadet version have been developed and successfully organised in 5 regional European workshops.
Prevent was originally developed in 1988 to estimate the health benefits of changes in risk factor prevalence for a population. Prevent is based on the epidemiological effect measure "potential impact fraction" (PIF), which derives a proportional change in disease risk from a change in risk factor exposure and the relative risk of that risk factor related to the disease(s) under study. Prevent first calculates the autonomous development of a health outcome of interest (here cancer incidence) by applying the trend impact fraction (TIF) on the baseline incidence rates. TIF and PIF are conceptually the same measure where TIF derives from historical changes in risk factor exposure and PIF from change of risk factor exposure due to an intervention. The proportional changes are calculated towards the predetermined theoretical minimum exposure value, the risk factor exposure that would result in the lowest population risk (e.g. in the case of smoking this would equal a smoking prevalence of 0). After the user specifies a change in risk factor prevalence due to an intervention, Prevent calculates the future incidence rates from the current situation using the TIF for the reference scenario and both PIF and TIF for the intervention scenario. The differences between the scenarios are attributed to the intervention, with the output given in terms of rates and number of expected cases in the future.
Risk factor prevalence data, cancer incidence data and relative risk estimates were combined into basic models for the different risk factors and cancers studied in Eurocadet. Then, the information on effectiveness of interventions was used to make assumptions regarding the effects that interventions might have on a population scale. Using Prevent modelling, several scenarios were made for different European countries and the different risk factors and cancers under study. These scenarios are extensively described in the final report of work package 7, and were largely published in a special issue of the European Journal of Cancer (Eur J Cancer 2010, 46: September 2010)
Use of PREVENT after the EUROCADET project
PREVENT has already been used to model health effects of interventions in the post-EUROCADET era, for example:
- in the DG Sanco project ‘EPIDERM' on epidemiology and primary prevention of skin cancer in Europe (results here), resulting amongst others in a publication on the potential impact of interventions to reduce UV radiation on skin cancer incidence.
- Soerjomataram et al showed using PREVENT that urban greenways have the potential to increase physical activity levels cost-effectively.
Want to make your own Prevent models?
If you want to work with Prevent you need:
- A clear hypothesis of an intervention on exposure to risk factors and health effects to be modelled
- Age- and sex specific incidence data from your country: the most recent estimated European data are available from EUCAN. These EUCAN data for 2012 are also published by Ferlay et al. You can also use the most recently observed incidence data (usually about 5 years old) provided by the registries to the EUREG database*.
- Prevalence data for the risk factors under study, from your own bureaus of statistics or you can use those collected by EUROCADET.
Publications on scenarios of future incidence of cancer in Europe based on Eurocadet:
- Boniol M, Autier P. Prevalence of main cancer lifestyle risk factors in Europe in 2000. Eur J Cancer. 2010 Sep;46(14):2534-44.
- Coebergh JW, Martin-Moreno JM, Soerjomataram I, Renehan AG. The long road towards cancer prevention: 4 steps backward and 8 forward. Eur J Cancer. 2010 Sep;46(14):2660-2.
- de Vries E, Soerjomataram I, Lemmens VE, Coebergh JW, Barendregt JJ, Oenema A, et al. Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction. Eur J Cancer. 2010 Sep;46(14):2605-16.
- Martin-Moreno JM, Alfonso-Sanchez JL, Harris M, Lopez-Valcarcel BG. The effects of the financial crisis on primary prevention of cancer. Eur J Cancer. 2010 Sep;46(14):2525-33.
- Menvielle G, Soerjomataram I, de Vries E, Engholm G, Barendregt JJ, Coebergh JW, et al. Scenarios of future lung cancer incidence by educational level: Modelling study in Denmark. Eur J Cancer. 2010 Sep;46(14):2625-32.
- Renehan AG, Soerjomataram I, Leitzmann MF. Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. Eur J Cancer. 2010 Sep;46(14):2581-92.
- Renehan AG, Soerjomataram I, Martin-Moreno JM, Coebergh JW. Foreword: Implementing cancer prevention in Europe. Eur J Cancer. 2010 Sep;46(14):2523-4.
- Soerjomataram I, de Vries E, Engholm G, Paludan-Muller G, Bronnum-Hansen H, Storm HH, et al. Impact of a smoking and alcohol intervention programme on lung and breast cancer incidence in Denmark: An example of dynamic modelling with Prevent. Eur J Cancer. 2010 Sep;46(14):2617-24.
* Through the FP7 ERANET project Eurocourse a special EUREG portal was made available in which European cancer registries can continuously upload their most recent incidence data plus active follow-up of potential date of death.